CCM
BBH icon

Coldstream Capital Management’s VanEck Biotech ETF BBH Stock Holding History

Coldstream Capital Management’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-150
Closed -$23.6K – 1345
2025
Q1 		$23.6K Buy
+150
New +$24.3K ﹤0.01% 2037

Other funds holding BBH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MIM
Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Coldstream Capital Management's BBH Position: Q2 2025 in Review

Coldstream Capital Management sold out of VanEck Biotech ETF (BBH) in Q2 2025, closing a stake of 150 shares — an estimated $23.6K sold.

Coldstream Capital Management first reported a position in BBH in Q1 2025 and held it in 1 quarter. The position peaked at $23.6K in Q1 2025. 98 funds tracked by Wall St. Rank hold BBH as of Q2 2025.

  • Coldstream Capital Management reported no remaining VanEck Biotech ETF position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 150 VanEck Biotech ETF shares in Q2 2025, an estimated $23.6K.
  • Coldstream Capital Management first reported a position in VanEck Biotech ETF in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's VanEck Biotech ETF position peaked at $23.6K in Q1 2025.
  • 98 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.